Patients with moderate congestive heart failure
Conditions
Interventions
None listed
Sponsors
Dokkyo Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria are included in this study. 1. First time ever to be admitted to this hospital for heart failure from the beginning of April 2008 to the end of July 2015 2. At age of 20 or older and started an oral agent of azosemide or furosemide during her/his stay in this hospital; however, anyone who started either oral agent before coming to this hospital did not change their dosage throughout the observation period can be qualified to be in this study. 3. Oral agent of azosemide or furosemide is continued for a year or longer with mild to moderate congestive heart failure, as well as those with the medication last less than a year and either deceased* or re-admitted* to the hospital. Patients with suspension of oral agents due to the use of furosemide injection during hospitalization can be enrolled. 4. With LVEF below 50%, hospitalization for heart failure is the first time 5. Heart condition categorized as mild to moderate congestive heart failure is stabled * For those who are deceased, the patient used azosemide or furosemide up to the death is qualified to this study. For those who are re-admitted, the patient continued to use azosemide or furosemide up to the re-admission is qualified to this study.
Exclusion criteria
Exclusion criteria: Patients who fall into any of the following criteria before discharge (from hospital) are excluded. The value "before discharge" means the last value collected before the patient leaves the hospital. 1. Blood glucose is inadequately controlled (hemoglobinA1c is over 9%, or over 200mg/dl at fasting state) 2. Symptomatic hypoglycemia 3. Inadequately controlled blood glucose with systolic blood pressure over 180mmHg 4. Serum Cr is over 2.5 mg/dl 5. Severe liver impairment, or any other acute and life-threating impairment 6. Has artificial auxiliary heart implanted 7. Complicated with severe chronic obstructive pulmonary disease or locality lung disease 8. Neither primary pulmonary hypertension nor left ventricular impairment is the cause of current pulmonary hypertension 9. Patients with acute coronary syndrome or cerebrovascular impairment, or underwent PCI or thoracotomy for cardiac surgery within last three months before hospitalization due to heart failure 10. Patients underwent treatment of cardiac resynchronization therapy, intraaortic balloon pumping, left ventricular assist device, or heart transplant due to heart failure 11. Severe cerebrovascular impairment 12. One type of loop diuretics other than azosemide or furosemide is prescribed 13. Currently using tolvaptan (Patients who temporally used tolvaptan during hospitalization can be enrolled) 14. Anyone who refuses to have their information used in this study 15. Patients need certain amount of azosemide or furosemide that is beyond health insurance coverage 16. Anyone with a condition judged by the physician (investigator) to be inappropriate for this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of "Cardiovascular death + Hospitalization for heart failure" | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are chosen based on J-MELODIC: * Incidences of "cardiovascular death", "hospitalization for heart failure" and "death caused by other reasons" * Change in CTR * Change in BNP * Change in LVEF (calculated based on the modified Simpson's rule) * Change in severity of heart failure (NYHA classification) * Change in other measured values | — |
Countries
Japan
Contacts
Public ContactHiroki Takayama
Soiken Inc. Clinical Study Support Division
Outcome results
None listed